Lv6
3092 积分 2023-04-07 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
17天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
17天前
已完结
A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer
1个月前
已完结
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody
1个月前
已完结
Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis
1个月前
已完结
Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in Diffuse Large B-Cell Lymphoma
2个月前
已完结
Age‐ and gender‐specific molecular characteristics of diffuse large B‐cell lymphoma: Results from clinical trials of the DSHNHL/GLA
2个月前
已完结
Unraveling ADC resistance in hematologic malignancies: Challenges and new frontiers
2个月前
已完结
Optimizing dose selection for doxorubicin-induced cardiotoxicity in mice: A comprehensive analysis of single and multiple-dose regimens
2个月前
已完结
Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies
3个月前
已完结
皖公网安备34019202002308
